The DOI matches its Crossref record; 334 of the 334 references it cites were found in a registry or an index; 174 of the 281 sources its claims cite were checked for support.
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Open accessAbstract
Integrating EVs with nanotechnology amplifies diagnostic and therapeutic capabilities, opening new avenues for managing CNS diseases.
Overview
CoChat Summary
## TL;DR
This is a review of how extracellular vesicles (EVs), often combined with nanotechnology, could improve diagnosis and treatment of central nervous system (CNS) disorders such as AD, PD, TBI, SCI, ALS, HD, and ischemic stroke. The paper argues that EVs are attractive because they can cross the BBB, carry diverse cargo, and be engineered for targeted theranostic applications, but it also emphasizes major remaining challenges in sensitivity, selectivity, stability, and delivery efficiency.
## Key findings
- EVs are presented as natural nanoscale carriers that can cross the BBB and transport proteins, lipids, nucleic acids, and drugs, making them promising for CNS theranostics.
- For AD, the review cites exosome-based biosensing with reported diagnostic performance such as 91.67% sensitivity, 95.00% selectivity, and 99.52% accuracy for combined exosomal miRNA-125b and miRNA-361, and another biosensor with 100% accuracy and Youden index of one for distinguishing AD from non-AD persons.
- For PD, plasma-derived EV α-syn was reported at higher levels in PD patients (n = 94) than healthy controls (n = 50), with one study reporting an AUC of 0.769 for distinguishing PD from healthy controls; another serum EV assay reported AUC 0.78.
- For TBI and SCI, the review highlights EV-based diagnostics and therapies, including brain-derived EV RNA profiling for TBI and multiple SCI studies in mice where EVs or engineered EVs improved repair, angiogenesis, axonal growth, inflammation, and functional recovery.
## Methods
- This is a narrative review of the literature on EVs and nanotechnology for CNS theranostics, organized by disorder (AD, PD, ALS, HD, TBI, SCI, ischemic stroke) and by diagnostic/therapeutic application.
- The paper synthesizes prior in vitro, in vivo, and clinical studies, including biosensor studies, biomarker studies, animal-model interventions, and examples of EV engineering and nanomaterial integration.
- It does not report a new dataset or original statistical analysis of its own; instead, it summarizes published studies and ongoing clinical trials.
## Limitations
- The paper states that many challenges remain, including problems with sensitivity, signal amplification, selectivity, repeatability, stability, and therapeutic delivery efficiency.
- It notes that early detection is still not foolproof because the origins and mechanisms of many CNS disorders are not fully understood, and single biomarkers are often not sufficiently selective; this is stated in the paper.
- It also makes evident that much of the evidence is based on preclinical in vitro and in vivo models, with the text noting a need for better in vitro models and improved clinical translation; this is evident from the review’s reliance on animal and assay studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Nanodiagnostic platforms for the detection of AD-derived EVs. (A) APEX assay schematics. (Top left), A representative schematic of changes in the transmission spectra with APEX amplification. (Top right), Finite-difference time-domain simulations show enhanced electromagnetic fields with back illumination. (Bottom left), and comparison of the detection sensitivities of APEX, enzyme-linked immunosorbent assay (ELISA), and western blotting. (Bottom right) Reproduced with permission from [232]. Copyright © 2019, The Author(s), (B) Schematic diagram of the detection process of the dual recognition of miRNA-193b and AβO42, Reproduced with permission from [236]. Copyright © 2023, American Chemical Society. and (C) Sensing scheme of the integrated nano-brush sensing substrate with the EGFET device (Top), SEM images show the presence of NFL-specific NDEs (white arrows), with atomic force microscopy (AFM) scan (inset) showing the surface roughness of post-NFL-sensing on nano-brush sensing substrates (Middle), schematic illustration depicting the important chemical bonds after sequential treatments and detection of NFL substances on the nano-brush sensing substrate (Bottom left), and Statistical analyses of the calibrated responses among the four tested groups (Bottom right). Reproduced with permission from [238]. Copyright © 2023, American Chemical Society](https://figures.cochat.ai/paper-figures/b0166652fb9845f2b9a992c61f214c74/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-3.jpg)
![Fig. 4 EV-based nanotherapeutic platforms for AD therapy. (A) Schematic diagram of the Lesion-Recognizing NPs and mechanism of the Lesion-Recognizing NPs for the synergistic treatment of AD (Top), Behavior improvement of the experimental mice. Time spent by mice in the target quadrant (Bottom left), Number of times the mice crossed the hidden platform (Bottom right). Reproduced with permission from [242]. Copyright © 2023, American Chemical Society, and (B) Schematic diagram of the gold nanoparticle-labeled exosome neuroimaging in AD (Top), and longitudinal homing and accumulation of MSC-exo in diseased brains (Bottom). Reproduced with permission from [244]. Copyright © 2019, American Chemical Society](https://figures.cochat.ai/paper-figures/63b51d0011fb43e4a510dfd6d7a1c567/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-4.jpg)
![Fig. 5 Engineered EV constructs for treatment of PD. (A) Schematic of PR-EXO/PP@Cur preparation. (I) (ROS)-responsive amphiphilic polymer PPS − PEG, curcumin and SPIONs were self-assembled into a micellar core. (II) MSC-derived sEVs were decorated with penetratin (P) and rabies virus glycoprotein (RVG29) peptides via hydrophobic carbon chains to form PR-EXO. (III) The inner micellar core and outer PR-EXO layer were combined by extrusion to construct the PR-EXO/PP@Cur. Reproduced with permission from [262]. Copyright © 2022, American Chemical Society. (B) Schematic of EV engineered with artificial module by conjugating L-arginine (L-Arg) with methacrylate anhydride (MA) to form arginine methacrylate (M-Arg). After crosslinking with BAC, zwitterionic nanoparticles poly (meth-acrylate arginine) (PMA) were prepared. Cross-linking agent sulfo-SMCC was reacted with PMA to form PMA-SMCC, which was subsequently combined with HUMSC derived EVs to form MSCEXO/PMA capable of migrating to the upregulated ROS and iNOS in the PD microenvironment. Reproduced with permission from [263]. Copyright © 2022 Wiley-VCH GmbH](https://figures.cochat.ai/paper-figures/eb2fdfa421a24478b528551677e80f47/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-5.jpg)
![Fig. 6 Native EVs and engineered EV constructs and therapeutic effects in ALS, HD, and ischemic stroke. (A) Improved motoneuron survival following administration of ASC-derived EVs quantified by (I) a stereological count of lumbar motoneuron and (II) Nissl staining. Reproduced with permission from [274]. Copyright © 2020 by the Authors. (B) Immunohistochemistry images of the striatum and spinal cord of R6/2 mice showing a decrease in HTT aggregates (brown spots) upon administration of XP-GFP-DNAJB6. Scale bar: 50 μm. Reproduced with permission from [280]. Copyright © 2021 by the Authors](https://figures.cochat.ai/paper-figures/63bf08f8db694da791ebdf46705595dc/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-6.jpg)
![Fig. 7 EV-based nanotheranostics for TBI. (A) A schematic representation of RVG29 decorating on the exosome surface using click chemistry. (B) Fluorescence images of primary neurons uptake RVG29 decorated exosomes. Scale bar = 75 μm, and (C) Representative images of whole brain and cresyl violet staining after controlled cortical impact insult for lesion volume check in different treatment groups (Left) and quantification of lesion volume. (Right). Reproduced with permission from [286]. Copyright © 2023 Elsevier B.V. All rights reserved](https://figures.cochat.ai/paper-figures/e909283c651f487280426578daa450f9/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-7.jpg)
![Fig. 8 EV-based nanotheranostics for SCI. (A) Schematic illustration of MN-MSC patch implantation on the injury site of the spinal cord (Top), and HE staining of the injured spinal cord with MN-MSC patch implantation (Bottom left), representative images of immunohistochemical staining for MN-MSC patches on the injured spinal cord on day 7 after SCI (Bottom center), and high-magnification images of the boxed area (Bottom right). Reproduced with permission from [296]. Copyright © 2023, The Author(s). (B) The mechanism of GMPE hydrogel promoting SCI repair (Left) and myelinated axons regeneration evaluated at the 6- and 12-week time points (Right) Reproduced with permission from [299]. Copyright © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH](https://figures.cochat.ai/paper-figures/c1b67f62abe6405681bcf671644e1b6c/extracellular-vesicles-as-nanotheranostic-platforms-for-targeted-neurological-figure-8.jpg)

Verification
Claims the paper makes
128 Valid · 7 Not valid · 63 Not checked · 42 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“EVs sourced from immune cells, such as DCs, macrophages, and natural killer (NK) cells, demonstrate an increased ability to evade immune clearance [38].”
§ Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions > Applications of EVs as nanotheranostic targets in CNS
What the sources say
- Disputedcites [38] P.D. Robbins, A.E. Morelli, Nat. Rev. Immunol. 14(3), 195–208 (2014) sourceExperimental — accuracy not yet measured
In “Therapeutic applications of immunoregulatory extracellular vesicles > APC-derived extracellular vesicles” (page unavailable), the review says injected dendritic-cell-derived EVs are rapidly cleared by phagocytic leukocytes—the opposite of the claimed ability to evade clearance. It does not establish increased clearance evasion for macrophage- or NK-cell-derived EVs. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, we cannot store the EVs for a long time since they lose their structure and bioactivity due to the destruction of the lipid layers [327–329].”
§ Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions > Conclusion and future perspectives
What the sources say
- Could not verifycites [327] J. Zhang, B. Ma, Z. Wang, Y. Chen, C. Li, Y. Dong, Cell. Commun. Signal. 22(1), 18 (2024) sourceExperimental — accuracy not yet measured
The composition of EVs section (page unavailable) says EVs have lipid bilayer structures, but does not say those layers are destroyed during storage. A passage in The function of therapy (page unavailable) describes MSC-derived exosomes as having “longer preservation” than MSCs; it gives no storage limit or evidence of lost structure or bioactivity. Searches for long-term storage, stability, and lipid-layer damage did not establish the claim. (LLM, conf=0.72)
- Disputedcites [328] C. Ma, R. Ding, K. Hao, W. Du, L. Xu, Q. Gao, C. Yu, Molecules 29(1) (2023) sourceExperimental — accuracy not yet measured
The Discussion (page not provided) recommends freezing EVs at −80 °C or below for long-term storage spanning days to months, contrary to the claim that they cannot be stored for a long time. It says repeated freeze–thaw cycles may damage EV membranes, but does not present lipid-layer destruction and loss of bioactivity as inevitable consequences of storage. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Could not verifycites [329] S. Bheri, M.E. Brown, H.J. Park, O. Brazhkina, F. Takaesu, M.E. Davis, ACS Nano. 17(20), 19613–19624 (2023) sourceExperimental — accuracy not yet measured
The Experimental Methods (Isolation and Characterization of sEVs; Synthesis of miR-Loaded ELVs with Electroporation; page numbers unavailable) say the vesicles were stored at −80 °C until use, but give no storage duration or evidence of deterioration. A search for long-term storage, loss of bioactivity, and lipid-bilayer damage found no passage addressing the claimed cause of storage limits. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, one of the biggest hurdles to managing CNS diseases is the difficulty of diagnosing them early.”
§ Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions > Introduction
What the sources say
- Not checked — no full text of the sourcecites [15] O. Hansson, Nat. Med. 27(6), 954–963 (2021) source
- Partly supportedcites [20] N. Swaddiwudhipong, D.J. Whiteside, F.H. Hezemans, D. Street, J.B. Rowe, T. Rittman, Alzheimers Dement. 19(5), 1752–1763 (2023) sourceExperimental — accuracy not yet measured
The Introduction says neurodegenerative-disease treatment trials typically begin after symptoms emerge, potentially too late to alter the disease course, and emphasizes understanding the pre-diagnostic phase. This supports early identification as a challenge for those diseases, but the paper does not establish that it is one of the biggest hurdles across CNS diseases generally. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neurological disorders, namely neurodegeneration and acute CNS injury, are overwhelmingly difficult maladies to treat and cure [101].”
§ Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions > Neurological disorders > Challenges of treating neurological disorders and limitations of current methods
What the sources say
- Partly supportedcites [101] L.K. Wareham et al., Mol. Neurodegener. 17(1), 23 (2022) sourceExperimental — accuracy not yet measured
The Conclusions (‘The challenge ahead’) call effective treatment or prevention of neurodegenerative disease a monumental challenge. ‘The promise of regeneration’ says the CNS has very limited capacity to repair itself after injury, but the paper does not specifically establish the claim about treating and curing acute CNS injury. (LLM, conf=0.82)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Due to the unique structure of the BBB, only small lipophilic molecules (molecular weights less than 500 Da) can diffuse across the BBB into the CNS [106].”
§ Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions > Neurological disorders > Challenges of treating neurological disorders and limitations of current methods
What the sources say
- Supportedcites [106] J.J. Lochhead, J. Yang, P.T. Ronaldson, T.P. Davis, Front. Physiol. 11, 914 (2020) source
The Introduction states that, under physiological conditions, only lipophilic molecules below 500 Da with few hydrogen-bond donors or acceptors can passively diffuse across the BBB. The claim accurately paraphrases the size and lipophilicity limits, though it omits the additional hydrogen-bonding criterion. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
132 more claims · 77 with their cited sources checked
Create a free account to see all 240 claims and to verify the 18 references still open.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 75
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
Research works printed but not linked: 9
- H. Lei, Z. Pei, C. Jiang, L. Cheng, Explor. (Beijing). 3(5), 20220001 (2023)
- Y. Ding, Y. Wang, Q. Hu, Explor. (Beijing). 2(3), 20210106 (2022)
- A.P. Porsteinsson, R.S. Isaacson, S. Knox, M.N. Sabbagh, I. Rubino, J. Prev. Alzheimers Dis. 8(3), 371–386 (2021)
- O. Hardiman, A. Al-Chalabi, A. Chio, E.M. Corr, G. Logroscino, W. Robberecht, P.J. Shaw, Z. Simmons, L.H. Van Den Berg, Nat. Reviews Disease Primers. 3(1), 1–19 (2017)
- C.S. Ahuja, J.R. Wilson, S. Nori, M. Kotter, C. Druschel, A. Curt, M.G. Fehlings, Nat. Reviews Disease Primers. 3(1), 1–21 (2017)
- M. Yanez-Mo et al., (eds.), J Extracell Vesicles 4(1), 27066 (2015)
- T.T. Yang, C.G. Liu, S.C. Gao, Y. Zhang, P.C. Wang, Biomed. Environ. Sci. 31(2), 87–96 (2018)
- J. Gill et al., Brain Inj. 32(10), 1277–1284 (2018)
- Y. Chen, H. Zhao, Z. Tan, C. Zhang, X. Fu, Pharmazie. 70(3), 147–154 (2015)
Cited by
Extracellular vesicles: New horizons in neurodegeneration
Chen, J., Tian, C., Xiong, X., Yang, Y., & Zhang, J. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105605 · Cited by 53
Extracellular vesicle therapy in neurological disorders
Putthanbut, N., Lee, J.-Y., & Borlongan, C. V. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01075-w · Cited by 48
Chen, M., Choi, H. K., Goldston, L. L., Hou, Y., Jiang, C., & Lee, K. (2025) · ACS Nano · doi:10.1021/acsnano.5c06940 · Cited by 48
Self-citationYang, Y., Nicol, C. J. B., & Chiang, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083915 · Cited by 38
“By providing these significant advantages over traditional therapies, Exos-coated NPs represent a promising and innovative approach to treating neurological diseases [167], potentially transforming patient outcomes and paving the way for more effective and personalized medical interventions.”
Wu, X., Liu, M., Wang, J., Liu, J., Zheng, M., Chan, P., Zhu, Q., Li, C., Kong, G., Tang, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c08573 · Cited by 17
Metadata
- Authors
- Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Lee, Ki-Bum
- ORCID
- Lee, Ki-Bum
- Venue
- Nano Convergence
- Published
- 2024-05-13
- Volume
- 11
- Issue
- 1
- Pages
- 19-19
- ISSN
- 2196-5404 (ISSN-L)
- PMC
- PMC11091041
- OpenAlex
- W4396857957
- Cited by
- 26
- References
- 332
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nano Convergence (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Foundation (CBET-1803517, DGE-2233066)
- New Jersey Commission on Spinal Cord Research (CSCR17IRG010, CSCR16ERG019)
- National Institutes of Health (R21-NS132556-01, 1R01DC016612, 1R01NS130836-01A1, 3R01DC016612-01S1, 5R01DC016612-02S1, RM1 NS133003-01)
- Alzheimer’s Association (AARG-NTF-21-847862)
- Congressionally Directed Medical Research Programs (OCRP, OC220235P1)
- New Jersey Commission on Cancer Research (COCR23PPR007)
- National Heart, Lung, and Blood Institute (U01HL150852)
- Zhou Family (Zhou Family)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Materials Chemistry › Advanced Nanomaterials in Catalysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- extracellular vesicles, nanotheranostics, central nervous system disorders, Alzheimer's disease, Parkinson's disease, traumatic brain injury, targeted drug delivery, biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions. https://app.cochat.ai/papers/10.1186/s40580-024-00426-5
- The paper
- Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024). Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions. Nano Convergence. https://doi.org/10.1186/s40580-024-00426-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.